RE:RE:RE:RE:RE:RE:RE:EY sees bolt-ons in the single to double digit billions now October 07, 2022 - Replimune secures US$200 Million in a non-dilutive financing loan facility to pursue the anti-PD-1 failed melanoma indication in which AMGEN's IT.OV Imlygic and MSD Keytruda had failed, as announced in early September 2022.
https://www.biospace.com/article/releases/replimune-secures-200-million-in-non-dilutive-debt-financing-from-hercules-capital-inc-/
https://www.medpagetoday.com/hematologyoncology/skincancer/100537
[ This ability for Replimue to raise cash in a failed OV/ICI applied indication further demonstrates that ONCY's Immune Molecule Platform Technology for use in various liquid and solid cancers is worth north of US$8 Billion ]